<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Lloyd-Jones, Donald M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Statins in the Water? Responsible Use of the Lipid-Modifying Drugs</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7-8</style></pages><abstract><style  face="normal" font="default" size="100%">To date, efforts toward primary prevention of cardiovascular disease have been focused on identifying patients who have a high estimated short-term risk. However, focusing solely on short-term risk does not adequately address younger and middle-aged individuals with moderate risk factor levels who may have low short-term but substantial lifetime risks for development of CVD [Lloyd-Jones DM et al. Circulation 2006].</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>